Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 8/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593961 | 0.87 | TPMT (0.48) | NQO2TPMTALDH1A1KDM4EHPGD | |
| SCHEMBL6078790 | 0.86 | NQO2 (0.52) | NQO2ALDH1A1KDM4EGAAPDE4D | |
| SCHEMBL6079519 | 0.82 | LMNA (0.54) | NQO2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2905353 | 0.74 | NQO2 (0.56) | NQO2ALDH1A1KDM4E | |
| SCHEMBL26235859 | 0.74 | NQO2 (0.44) | NQO2TPMTALDH1A1KDM4EGAA | |
| SCHEMBL30563792 | 0.74 | NQO2 (0.44) | NQO2TPMTALDH1A1KDM4EGAA | |
| SCHEMBL9379118 | 0.73 | NQO2 (0.51) | NQO2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL8755932 | 0.73 | LCK (0.47) | NQO2ALDH1A1KDM4EGAALCK | |
| SCHEMBL29128041 | 0.71 | NQO2 (0.42) | NQO2ALDH1A1KDM4EGAALCK | |
| SCHEMBL9380176 | 0.70 | NQO2 (0.48) | NQO2KDM4ELCKNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | NQO2 2/4885TPMT 492/4885ALDH1A1 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.